๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› China
Clinical trial register · China

Studies with a Chinese investigative site

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the register
Recruitment status
Phase
Lead sponsor
Sun Yat-sen University490 Fudan University472 Second Affiliated Hospital, Zhejiang University, School of Medicine404 Peking Union Medical College Hospital282 Ruijin Hospital281
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to
19052 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer
NCT07458529Rectal Cancer, Adenocarcinoma, Neoadjuvant Therapy, Immunotherapy, Probio-M9
Seventh Medical Center of PLA General Hospital
Phase 2
50
Beijing
2026-02-10
Recruiting
Correlating EEG Dynamics With Consciousness Alteration Under Anesthesia
NCT07410702Altered State of Consciousness, General Anesthetics
Huazhong University of Science and Technology
Observational
250
Wuhan
2026-02-10
Not yet open
Assessing Hydromorphone Sustained-Release Tablets in Elderly Cancer Pain Patients With Renal Insufficiency
NCT07421674Cancer Pain, Renal Insufficiency Chronic, Hydromorphone Use
Taian Cancer Hospital
Observational
62
Taiโ€™an
2026-02-10
Not yet open
Phase 2 Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Platinum Chemotherapy Versus Platinum Chemotherapy in the Treatment of Second-/Third-line Triple Negative Breast Cancer (TNBC)
NCT07413601Triple Negative Breast Cancer Metastatic
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
78
Beijing
2026-02-10
Not yet open
ctDNA Monitoring Guides the Treatment of NSCLC With Befotertinib Combined With Radiotherapy
NCT07410611Patients With Advanced Oligometastatic Non-small Cell Lung Cancer (NSCLC) Who Have Tested Positive for EGFR Mutations Confirmed by Histopathological Examination
Hebei Medical University Fourth Hospital
Phase 2
84
Shijiazhuang
2026-02-10
Recruiting
Study on the Treatment of HER2-negative Breast Cancer Brain Metastases With Radiotherapy Combined With Anlotinib
NCT07396454HER2-Negative Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2
39
Nanjing
2026-02-10
Recruiting
Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma
NCT07416890Pirtobrutinib, Sintilimab, Central Nervous System Lymphoma
Zhejiang Cancer Hospital
Phase 2
24
Hangzhou
2026-02-10
Recruiting
Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis
NCT07335887AL Amyloidosis (AL), t(11;14) Positive
Peking University People's Hospital
Phase 2
39
Beijing, Xi'an
2026-02-10
Recruiting
Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy
NCT07400523Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3
446
Zhanjiang, Guangzhou, Shantou
2026-02-10
Recruiting
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
NCT07227415Carcinoma, Renal Cell, Advanced Renal Cell Carcinoma, Renal Cancer, Renal Neoplasm
Pfizer
Phase 1/2
224
Beijing, Chongqing, Wuhan, Changsha, Nanjing, Jinan, Ningbo
2026-02-10
Recruiting
NWRD09 for Persistent Cervical HPV16 Infection
NCT07710703Persistent Cervical HPV16 Infection
Newish Biotech (Wuxi) Co., Ltd.
Not applicable
60
Beijing
2026-02-10
Recruiting
Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy
NCT07496190Nasopharyngeal Cancinoma (NPC)
Sun Yat-sen University
Phase 2
59
Guangzhou
2026-02-10
By invitation
Early Postoperative Intervention in Gastric Cancer Patients
NCT07444099Gastric Cancer (GC), Postoperative Recovery
Qilu Hospital of Shandong University
Not applicable
264
Jinan
2026-02-10
Recruiting
A Study of Brenipatide in Adult Participants With Schizophrenia
NCT07410507Schizophrenia
Eli Lilly and Company
Phase 2
450
Changsha, Chengdu, Hangzhou, Suzhou, Tianjin, Wuhu, Xi'an, Zhumadian
2026-02-10
Not yet open
Research Proposal on the Effects of Different Altitude Conditions on Human Time Perception.
NCT07402148Heart Rate Monitoring
Qilu Hospital of Shandong University
Observational
46
Jinan
2026-02-10
Recruiting
A Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nasopharyngeal Carcinoma
NCT07392320Nasopharangeal Cancer
Sun Yat-sen University
Phase 2
142
Guangzhou
2026-02-10
Recruiting
Flow Diverter Versus Conventional Endovascular Treatment for Unruptured Wide-Neck Bifurcation Aneurysms (FD-BWA Trial)
NCT07707076Unruptured Intracranial Wide-neck Bifurcation Aneurysms
Nanfang Hospital, Southern Medical University
Not applicable
266
Guangzhou
2026-02-10
Recruiting
Safety and Efficacy of Cryoablation for Thyroid Tumors
NCT07776262Thyroid Tumor, Thyroid Neoplasm
Yukun Luo
Not applicable
108
Beijing
2026-02-09
Recruiting
Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.
NCT06059261Nasopharyngeal Carcinoma
Chongqing University Cancer Hospital
Phase 2
30
Chongqing
2026-02-09
Recruiting
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
NCT07353931Osteoarthritis, Overweight or Obesity
Eli Lilly and Company
Phase 3
900
Beijing, Bengbu, Changchun, Changsha, Chongqing, Hangzhou, Hefei, Jinan
2026-02-09
Recruiting
A Retrospective Study to Evaluate Treat-to-Target and Disease Modification in Adult Participants With Crohn's Disease and Ulcerative Colitis in Real World Setting
NCT07421258Crohn's Disease, Ulcerative Colitis
AbbVie
Observational
2,000
Chongqing
2026-02-09
Recruiting
Remimazolam for Bronchoscopy in High-Risk Patients
NCT07395596Pulmonary Infection, Pulmonary Nodule, Phthisis, Endotracheal Tumour
First Affiliated Hospital of Zhejiang University
Phase 4
360
Hangzhou, Shaoxing
2026-02-09
Recruiting
A Study of XW003 in Obese Participants With Obstructive Sleep Apnea But Not Receive Positive Airway Pressure Therapy
NCT07387094OSA - Obstructive Sleep Apnea, Obesity
Hangzhou Sciwind Biosciences Co., Ltd.
Phase 3
140
Beijing
2026-02-09
Not yet open
Effectiveness and Safety of a Type A Dissection Total Endovascular Reconstruction System in Promoting Favorable Distal Aortic Remodeling
NCT07402252Residual Dissection After Repair for Type A Aortic Dissection
West China Hospital
Not applicable
198
Chengdu
2026-02-09
Recruiting
Study on the Prevention of Atrial Fibrillation Recurrence After Ablation by Qidong Yixin Granule
NCT07508618Persistent Atrial Fibrillation
Sir Run Run Shaw Hospital
Phase 4
846
Hangzhou, Huzhou, Ningbo
2026-02-09
By invitation
Safety and Efficacy of B/F/TAF in Pregnancy
NCT07666386HIV
Shi Zou
Observational
50
Wuhan
2026-02-09
Recruiting
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
NCT07412756Depressive Disorder, Major
Eli Lilly and Company
Phase 3
1,000
Beijing, Changsha, Chengdu, Guangzhou, Haidian District, Hefei, Huzhou, Jining
2026-02-09
Recruiting
Blood Pressure Monitor (TH-75) Atrial Fibrillation Detection Function Clinical Trial
NCT07442175Atrial Fibrillation (AF)
Andon Health Co., Ltd
Observational
392
Tianjin
2026-02-09
Recruiting
The Efficacy and Safety of SHR4640 Tablet Combined With 40 mg Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia
NCT07362355Primary Gout and Hyperuricemia
Jiangsu HengRui Medicine Co., Ltd.
Phase 2
340
Shanghai
2026-02-09
Recruiting
The Value of Super-resolution Ultrasound Imaging for Peripheral Artery Disease
NCT07374601Peripheral Artery Disease
Peking University First Hospital
Observational
300
Beijing
2026-02-08
Active, closed
Study of TRDC002 in the Diagnosis of Patients With PSMA-positive Prostate Cancer
NCT07236112Prostate Cancer
C Ray Therapeutics
Phase 1
6
Wuhan, Jinan
2026-02-08
Recruiting
Advancing Reperfusion Therapy for Ischemic Stroke: Perfusion-guided Endovascular Intervention for Medium Vessel Occlusion Therapy
NCT07323368Stroke Ischemic, Medium Vessel Occlusions
Beijing Tiantan Hospital
Not applicable
568
Beijing, Longzhou, Luoyang, Panlong, Changle
2026-02-08
Recruiting
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
NCT07266441Multiple Myeloma
Janssen Research & Development, LLC
Phase 2
157
Beijing, Chaoyang District, Guangzhou, Shanghai
2026-02-08
Recruiting
PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.
NCT07410520Primary Central Nervous System Lymphoma (PCNSL), Secondary Central Nervous System Lymphoma (SCNSL)
The First Affiliated Hospital with Nanjing Medical University
Phase 2
50
Nanjing
2026-02-07
Recruiting
A Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic Dermatitis
NCT07399067Atopic Dermatitis
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2
120
Beijing
2026-02-06
Recruiting
Becotatug Vedotin (MRG003) in Combination With PD-1 Inhibitor Versus PD-1 Inhibitor for the Treatment of EGFR-positive, CPSโ‰ฅ1 Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT07524452Locally Advanced Head and Neck Squamous Cell Carcinoma
Ming-Yuan Chen
Phase 3
430
Zhuhai
2026-02-06
Recruiting
A Dose-exploration Study of EDP167 in HoFH
NCT07489209Homozygous Familial Hypercholesterolemia (HoFH)
Eddingpharm (Zhuhai) Co., Ltd.
Phase 2
20
Beijing
2026-02-06
Recruiting
A Study of PLB-002 in Advanced Solid Tumors
NCT07304128Advanced Solid Tumor
Primelink BioTherapeitics(ShenZhen) Limited
Phase 1
100
Shanghai
2026-02-06
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
NCT07321886Obesity, Overweight
Eli Lilly and Company
Phase 3
1,980
Beijing, Chengdu, Guangzhou, Hefei, Jinan, Luoyang Shi, Nanchang, Nanjing
2026-02-06
Not yet open
A Dose Finding Study of IBI3016 in Mild to Moderate Hypertensive Patients
NCT07352969Hypertension
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2
352
Beijing
2026-02-06
Recruiting
Efficacy and Safety of SBRT Combined With Becotatug Vedotin (MRG003) in EGFR-Positive Metastatic Tumor Patients With Oligometastases
NCT07481799Oligo-metastatic Cancer
Ming-Yuan Chen
Phase 3
200
Zhuhai
2026-02-06
Recruiting
A Study on the Correlation Between Tear Iron Levels and the Severity of Dry Eye Disease.
NCT07363824Dry Eye Disease, Iron
Shanghai Changzheng Hospital
Observational
52
Shanghai
2026-02-06
Recruiting
Comparison of Serplulimab Versus Nivolumab in Neoadjuvant Therapy for Resectable Stage II-IIIA Squamous NSCLC
NCT07398937Resectable Stage II-IIIa Squamous NSCLC
Fudan University
Phase 2
116
Shanghai
2026-02-05
Recruiting
A Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy.
NCT07375758Immunoglobulin A Nephropathy
Beijing Mabworks Biotech Co., Ltd.
Phase 1/2
130
Beijing
2026-02-05
Recruiting
Early Neurovascular Decoupling Trajectories After Revascularization in Acute Ischemic Stroke
NCT07405762Ischemic Stroke
Xijing Hospital
Observational
180
Xi'an
2026-02-05
Not yet open
A Multi-modal Integrating Imaging and Cell-free DNA Methylation in Lung Cancer Early Detection (CMe-Lung): a Multi-center, Observational Study
NCT07375979Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Observational
14,300
Shijiazhuang, Zhengzhou, Changchun, Shenyang, Shanghai, Kunming
2026-02-05
Not yet open
The Influence of Explainability and Integrability of AI-CDSS on Usage Behavior Among Primary Care Physicians
NCT07401979Respiratory Tract Infections (RTI)
Huazhong University of Science and Technology
Not applicable
3,000
Wuhan
2026-02-05
Recruiting
An Antibody-armored Dendritic Cell in Patients With Solid Tumors
NCT07479667Solid Cancers, Adjuvant Therapy
Shanghai Cell Therapy Group Co.,Ltd
Phase 1
8
Shanghai
2026-02-05
Recruiting
A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma
NCT07377578Mantle Cell Lymphoma
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 3
394
Beijing, Nanning
2026-02-05
Recruiting
Multimodal AI for Predicting Response to Neoadjuvant Immunotherapy in Gastric Cancer (PRISM-GC)
NCT07401199Gastric Cancer (GC), Locally Advanced Gastric Cancer
Qun Zhao
Observational
2,000
Fuyang, Cangzhou, Hengshui, Xingtai, Wuhan, Yichang, Baoding, Shijiazhuang
2026-02-05
Recruiting
Study of Single and Multiple Ascending Doses of KR23343 in Healthy Adult Participants
NCT07409922Healthy
Jiangxi Kvvit Pharmaceutical Co., Ltd.
Phase 1
92
Shanghai
2026-02-05
Recruiting
A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer
NCT07253142Non Small Cell Lung Cancer, Small Cell Lung Cancer
Shanghai Henlius Biotech
Phase 2
120
Hefei, Fu'zhou, Guangzhou, Nanning, Cangzhou, Harbin, Xinxiang, Wuha
2026-02-05
Recruiting
TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD
NCT07487363Atherosclerotic Cardiovascular Diseases, Endothelial Dysfunction
Hudson Biotech
Phase 1/2
80
Shenzhen
2026-02-05
Recruiting
High-flow Nasal Cannula Versus Conventional Oxygen During Awake Tracheal Intubation With Difficult Airways
NCT07384494Awake Tracheal Intubation, Difficult Airway
Wenxian Li
Not applicable
336
Wuwei, Shenzhen, Baoding, Pizhou, Shanghai, Neijiang
2026-02-04
Recruiting
Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRฮฑ, MUC16)
NCT07480954Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Carcinoma, Recurrent or Refractory Disease After Standard Therapies
Beijing Biotech
Phase 1/2
36
Shenzhen
2026-02-04
Active, closed
Predicting Pathological Complete Response in Rectal Cancer Using Machine Learning
NCT07509632Rectal Cancers, Pathological Complete Response, Neoadjuvant Chemoradiotherapy, Machine Learning
Peking University People's Hospital
Observational
320
Beijing
2026-02-04
Recruiting
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
NCT07258511Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
400
Beijing, Chengdu, Guangzhou, Hangzhou, Nanjing, Nanning, Shanghai, Wenzhou
2026-02-04
Recruiting
A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
NCT07276958Healthy, Systemic Lupus Erythematosus, Rheumatoid Arthritis
Eli Lilly and Company
Phase 1
68
Beijing, Changsha, Hefei, Shanghai, Wenzhou, Wuhan
2026-02-04
Recruiting
Real-world Use of Lutetium (177Lu) Vipivotide Tetraxetan in China(PSMAreal CN)
NCT07290270Metastatic Prostate Cancer
Novartis Pharmaceuticals
Observational
170
Shanghai
2026-02-04
Recruiting
Autologous CAR-T Cell Therapy for Refractory and Relapsing Ulcerative Colitis: A Single-Center Exploratory Study
NCT07435779UC
Hebei Senlang Biotechnology Inc., Ltd.
Phase EARLY_PHASE1
12
Guangzhou
2026-02-04
Not yet open
IBI363 as Neoadjuvant Therapy in Resectable Stage II-III Non-Small Cell Lung Cancer
NCT07402070Resectable Stage II-III Non-small Cell Lung Cancer
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2
10
Beijing
2026-02-04
Recruiting
Clinical Study of AFN50 Injection in the Autoimmune Diseases
NCT07408336Autoimmune Diseases
AlphaNa Bioscience Company Limited
Phase EARLY_PHASE1
18
Hefei
2026-02-04
Recruiting
A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer
NCT07325136Relapsed/Refractory Small Cell Lung Cancer
Bristol-Myers Squibb
Phase 1/2
240
Beijing, Shanghai
2026-02-03
Recruiting
Safety and Efficacy Study of PUMCH-E111 Injection in Subjects With RLBP1 Related Inherited Retinal Dystrophy
NCT07656753Inherited Retinal Dystrophy, Inherited Retinal Disease
Peking Union Medical College Hospital
Phase EARLY_PHASE1
6
Beijing
2026-02-03
Recruiting
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
NCT07431281Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer
AstraZeneca
Phase 3
2,130
Beijing, Changde, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin
2026-02-03
Recruiting
Efficacy and Influencing Factors of Mindfulness-Based Exposure Group Therapy for OCD
NCT07484750Obessive-Compulsive Disorder
Shanghai Mental Health Center
Not applicable
64
Shanghai
2026-02-03
By invitation
CHU Dual-Energy Ablation in Ventricular Arrhythmia
NCT07503769Premature Ventricular Contractions, Ventricular Tachycardia
Shanghai MicroPort EP MedTech Co., Ltd.
Not applicable
10
Ningbo
2026-02-03
Recruiting
A Phase II Clinical Study Evaluating of ZL-82 Tablets in Atopic Dermatitis
NCT07193589Atopic Dermatitis
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 2
111
Chengdu
2026-02-03
Recruiting
CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL
NCT07397832Diffuse Large B-Cell Lymphoma (DLBCL)
Tianjin Medical University Cancer Institute and Hospital
Phase 2
58
Tianjin
2026-02-03
Recruiting
UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological Diseases
NCT07441525Autoimmune Hemolytic Anemia, Primary Immune Thrombocytopenic Purpura, Evans Syndrome
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase EARLY_PHASE1
27
Wuhan
2026-02-03
Recruiting
PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Selective Re-irradiation for Locally Advanced Recurrent NPC
NCT07332247Nasopharangeal Cancer, Recurrent Nasopharynx Carcinoma
Sun Yat-sen University
Phase 2
94
Guangzhou
2026-02-03
Recruiting
A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC
NCT07264816Non-squamous Non-small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
80
Wuhan
2026-02-03
Recruiting
Arch-Clamping Technique Under Mild Hypothermia in Treating With Acute Type A Aortic Dissection
NCT07150559Acute Type A Aortic Dissection, Hypothermia, Total Aortic Arch Replacement, Frozen Elephant Trunk
Beijing Anzhen Hospital
Not applicable
306
Beijing
2026-02-03
Recruiting
Fecal Microbiota Transplantation for Ulcerative Colitis Using Dai and Han Donors
NCT07814456Ulcerative Colitis (UC), Inflammatory Bowel Disease
First Affiliated Hospital of Kunming Medical University
Phase 2
200
Kunming
2026-02-03
Recruiting
Olanzapine Plus Metoclopramide for the Prevention of Opioid-Induced Nausea and Vomiting
NCT07208305Nausea, Vomiting
Affiliated Hospital of Qinghai University
Phase 3
222
Xining
2026-02-03
Recruiting
A Study for HSK47388 in Participants With Ulcerative Colitis
NCT07335055Ulcerative Colitis (UC)
Haisco Pharmaceutical Group Co., Ltd.
Phase 2
150
Hangzhou
2026-02-03
Recruiting
Telemedicine-supported Management for Acute Ischemic Stroke
NCT07302971Acute Ischemic Stroke
Capital Medical University
Not applicable
2,400
Beijing
2026-02-02
Recruiting
A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
NCT07311694PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
370
Shanghai
2026-02-02
Recruiting
Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
NCT07480928Pancreatic Ductal Adenocarcinoma (PDAC), Unresectable Locally Advanced or Metastatic Disease
Beijing Biotech
Phase 1/2
42
Shenzhen
2026-02-02
Recruiting
Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)
NCT07486089Breast Cancer (Locally Advanced or Metastatic), HER2-positive Breast Cancer, Triple-Negative Breast Cancer (TNBC)
Beijing Biotech
Phase 1/2
60
Shenzhen
2026-02-02
Recruiting
Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC
NCT07467863Non-Small Cell Lung Cancer, Advanced/Metastatic NSCLC
Beijing Biotech
Phase 1/2
48
Shenzhen
2026-02-02
Recruiting
Guangdong Provincial Endometriosis Clinical Research Cohort
NCT07749053Endometriosis
Li Li
Observational
716
Guangzhou
2026-02-02
Recruiting
MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity
NCT07505745Prediabetes, Insulin Resistance, Overweight/Obesity
Hudson Biotech
Phase 2
120
Shenzhen
2026-02-02
Recruiting
A Study of GR1803 in Systemic Lupus Erythematosus
NCT07348055Systemic Lupus Erthematosus, Auto Immune Disease
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Phase 1/2
44
Wuhan
2026-02-02
Recruiting
Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma
NCT07551349Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Beijing Biotech
Phase 1/2
36
Shenzhen
2026-02-02
Recruiting
Study of Radiotherapy Combined With Cisplatin/Carboplatin, Adebrelimab and Bevacizumab in the Treatment of TNBC-BM.
NCT07638852TNBC, Triple Negative Breast Cancer, Brain Metastasases
Fudan University
Phase 2
58
Shanghai
2026-02-02
Recruiting
Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer
NCT07589517Colorectal Cancer, Metastatic Colorectal Adenocarcinoma, Unresectable Colorectal Cancer
Beijing Biotech
Phase 1/2
48
Shenzhen
2026-02-02
Not yet open
Correlation Between EIT-based Pulse Wave Method for Pulmonary Perfusion Monitoring and Pulmonary Artery Catheter-based Stroke Volume Measurement
NCT07385963Shock, Acute Respiratory Distress Syndrome
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Observational
19
Wuhan
2026-02-02
Recruiting
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)
NCT07481747Obesity, Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities
Hudson Biotech
Phase 3
2,539
Shenzhen
2026-02-02
Recruiting
Impact of Mindfulness on Athletic Performance and Functional Movement in Collegiate Athletes
NCT07342816Athletic Performance, Mental Health
University of Macau
Not applicable
126
2026-02-02
Recruiting
Y-4 to Treat the Postherpetic Neuralgia
NCT07275762Postherpetic Neuralgia, Y-4, Pregabalin
Neurodawn Pharmaceutical Co., Ltd.
Phase 2
160
Nanjing
2026-02-02
Recruiting
Topical GHK-Cu Gel for Acute Skin Wound Healing
NCT07437586Acute Standardized Cutaneous Wounds (Punch-biopsy Wounds)
Hudson Biotech
Phase 2
60
Shenzhen
2026-02-02
Recruiting
Efficacy and Safety of YD0743 Treatment for Sepsis-Associated ARDS
NCT07413094Sepsis
Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.
Phase 2
309
Beijing
2026-02-02
Recruiting
Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer
NCT07393425HER2 + Breast Cancer
Shanghai Jiao Tong University School of Medicine
Phase 2
50
Shanghai
2026-02-02
Not yet open
Efficacy and Safety of LP-005 Injection in Patients With Complement-Mediated Kidney Disease
NCT07363265Complement-mediated Renal Diseases
Longbio Pharma
Phase 2
46
Beijing
2026-02-02
Recruiting
Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma
NCT07480941Glioblastoma, High-grade Glioma, Malignant Glioma, Recurrent Glioblastoma
Beijing Biotech
Phase 1
36
Shenzhen
2026-02-02
Recruiting
Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)
NCT07481734Metabolic Associated Steatotic Liver Disease, Nonalcoholic Steatohepatitis, Hepatic Steatosis
Hudson Biotech
Phase 2
120
Shenzhen
2026-02-02
Recruiting
Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo
NCT07437560NonSegmental Vitiligo, Nonsegmental Vitiligo (Stable)
Hudson Biotech
Phase 2
60
Shenzhen
2026-02-02
By invitation
Neurofeedback Training of Anterior Insula Activity Based on Unidimensional vs. Multidimensional Interoceptive Regulation Strategies
NCT07416370Healthy
University of Electronic Science and Technology of China
Not applicable
60
Chengdu
2026-02-02
Recruiting
BPC 157 for Acute Hamstring Muscle Strain Repair
NCT07437547Hamstring Muscle Strain, Skeletal Muscle Injury
Hudson Biotech
Phase 2
120
Shenzhen
2026-02-02
Rows per page Showing 3801–3900 of 19052
Previous 37 38 39 40 41 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site. Derived from ClinicalTrials.gov. Retrieved 23 September 2026. https://priyalifescience.com/clinical-trials-china?page=39

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →
→

Browse trials by condition

Breast Cancer (416) Advanced Solid Tumors (183) Gastric Cancer (183) Colorectal Cancer (179) Hepatocellular Carcinoma (161) Advanced Solid Tumor (159) Solid Tumor (145) Non-Small Cell Lung Cancer (144) Acute Ischemic Stroke (138) Lung Cancer (134) Pancreatic Cancer (132) Non-small Cell Lung Cancer (131) Multiple Myeloma (126) Coronary Artery Disease (111) Prostate Cancer (111)
→

Browse trials by site location

Beijing (5484) Shanghai (3827) Guangzhou (3318) Hangzhou (1812) Wuhan (1343) Chengdu (1291) Nanjing (1193) Changsha (1154) Chongqing (1056) Fuzhou (1018) Tianjin (940) Zhengzhou (921) Hefei (875) Jinan (785) Changchun (641)
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.